Eqdomin

Detomidine hydrochloride 10 mg/mL. Sedative for Equine

Anesthetics / Sedatives
  • Equinos

Components:

Each 1 mL contains:

Detomidine hydrochloride .......... 10 mg

Vehicle q.s. .......... 1 mL


Eqdomin is a sedative made from Detomidine hydrochloride, an agonist to alpha adrenergic receptors, pre-synaptically located, which, when stimulated prevent the release of noradrenaline through the inhibition of the inflow of Ca++ ions in the neuronal membrane. This stimulation has hypotensive and calming effect, the latter a result of the decrease of the activity of ascending noradrenergic projection of the reticular formation. Among the effects of the CNS observed when using this drug are sedation, hypnosis, muscle relaxation, ataxia, vasomotor center depression and increase of vagal tone and baroreceptors. Detomidine has also a low molecular weight and, due to its highly lipophilic behavior, is highly absorbed, with strong affinity to central nervous system. When compared to xylazine (widely used drug), it has more sedative power, with further specificity for alpha adrenergic receptors. It also presents a long lasting action, with identical pharmacological effect.


Indication:

Eqdomin is indicated for the sedation of equine, when necessary, such as the performance of clinical and complementary exams, collection of biological material for laboratory exams and to carry out simple surgical interventions.


Directions and Dosage:

Eqdomin must be administered through the intravenous route (IV), at the dose of 0,02 mg/kg, equivalent to 0,2 mL for every 100 kg bodyweight, according to the table in the leaflet.

At the efficiency study carried out with Eqdomin, animals presented the beginning of sedation, from 1 to 5 minutes after its administration (satisfactory sedation 30 to 60 minutes after its administration). This period is variable, according to the characteristics of each animal and procedure to be carried out. Eqdomin is indicated to be used in a single dose. The application of complementary doses to the initial dose must be evaluated by the veterinarian, considering each case.


CAUTION: COMPLY WITH THE FOLLOWING GRACE PERIOD

THE PRODUCT DOES NOT REQUIRE GRACE PERIOD FOR THE SLAUGHTER OF TREATED EQUINE.


Last update: 10-26-2023

Presentations:

  • Flask with 5 mL.